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Abstract
Background and Objectives We propose a strategy for
studying ethnopharmacology by conducting sequential
physiologically based pharmacokinetic (PBPK) prediction
(a ‘bottom-up’ approach) and population pharmacokinetic
(popPK) confirmation (a ‘top-down’ approach), or in reverse
order, depending on whether the purpose is ethnic effect
assessment for a new molecular entity under development or
a tool for ethnic sensitivity prediction for a given pathway.
The strategy is exemplified with bitopertin.
Methods A PBPK model was built using Simcyp to
simulate the pharmacokinetics of bitopertin and to predict the
ethnic sensitivity in clearance, given pharmacokinetic data in
just one ethnicity. Subsequently, a popPK model was built
using NONMEM to assess the effect of ethnicity on
clearance, using human data from multiple ethnic groups. A
comparison was made to confirm the PBPK-based ethnic
sensitivity prediction, using the results of the popPK analysis.
Results PBPK modelling predicted that the bitopertin
geometric mean clearance values after 20 mg oral adminis-
tration in Caucasians would be 1.32-fold and 1.27-fold
higher than the values in Chinese and Japanese, respectively.
The ratios of typical clearance in Caucasians to the values in
Chinese and Japanese estimated by popPK analysis were
1.20 and 1.17, respectively. The popPK analysis results were
similar to the PBPK modelling results.
Conclusion As a general framework, we propose that
PBPK modelling should be considered to predict ethnic
sensitivity of pharmacokinetics prior to any human data and/
or with data in only one ethnicity. In some cases, this will be
sufficient to guide initial dose selection in different ethnici-
ties. After clinical trials in different ethnicities, popPK
analysis can be used to confirm ethnic differences and to
support dose justification and labelling. PBPK modelling
prediction and popPK analysis confirmation can comple-
ment each other to assess ethnic differences in pharma-
cokinetics at different drug development stages.
Key Points
Physiologically based pharmacokinetic (PBPK)
prediction and population pharmacokinetic
confirmation can complement each other to assess
ethnic differences in the pharmacokinetics of new
molecular entities (NMEs) at different drug
development stages.
For NMEs involving well-defined pharmacokinetic
processes with well-established PBPK models,
especially for those low-ethnic-sensitivity pathways
that are defined, dedicated pharmacokinetic bridging
studies may not be needed.
Successful application of this strategy may be
facilitated by an academic–industry–regulatory
consortium to collect ethnic-specific system data and
to develop and validate PBPK models of the major
pharmacokinetic processes.
Electronic supplementary material The online version of this
article (doi:10.1007/s40262-015-0356-1) contains supplementary
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1 Introduction
In recent years, there has been a dramatic increase in the
number of global clinical trials [1, 2]. This trend offers
opportunities for cost saving and recruitment acceleration,
as well as minimizing duplication of clinical data and
shortening the drug approval gap among regions. However,
heterogeneity due to ethnic differences is a potential con-
cern and needs to be addressed to allow successful global
clinical trials [3]. Traditional exploratory pharmacokinetic/
pharmacodynamic (PK/PD) bridging studies that assess
ethnic differences face a number of challenges. Financially,
it is costly to frontload early exploratory PK/PD bridging
studies for every molecule entering phase 1 and, techni-
cally, such studies may not be able to draw adequate
conclusions about the size of the ethnic effect, because of
large PK/PD variability, small sample sizes or sex imbal-
ances between ethnic groups. Ethnic sensitivity prediction
using physiologically based pharmacokinetic (PBPK)
modelling (a ‘bottom-up’ approach) offers the potential to
support early decision making on the timing and design of
bridging studies because it can be performed prior to first-
in-man studies and/or at a time when pharmacokinetic data
in only one ethnicity are available. Then, when in vivo
pharmacokinetic data in different ethnic groups are avail-
able, population pharmacokinetic (popPK) analysis (a ‘top-
down’ approach) can be used to confirm the PBPK pre-
diction and fulfil regulatory requirements.
Bitopertin (RG1678, RO4917838) is a glycine reuptake
inhibitor, which is postulated to improve N-methyl-D-as-
partate (NMDA) receptor hypofunction by increasing the
synaptic concentration of glycine, an obligatory co-agonist
at the NMDA receptor [4–6]. Bitopertin is a lipophilic
molecule showing rapid and extensive distribution into
tissues, and slow clearance in Caucasians [7]. Absorption
of bitopertin is good (simulated bioavailability by a vali-
dated PBPK model in humans is[90 % at doses\80 mg)
but slightly less than dose proportional at doses[50 mg
because of the low solubility and incomplete absorption of
the dose [8]. In vitro and in vivo studies have shown that
cytochrome P450 (CYP) 3A4 is the major enzyme
responsible for metabolism of bitopertin [7].
We propose a strategy for ethnopharmacology whereby
bottom-up and top-down approaches are applied in a
complementary fashion. For a new molecular entity
(NME), PBPK modelling can be applied to make an early
prediction of ethnic sensitivity. As clinical data sets
become available, the effects of ethnic differences are
quantified through a robust popPK analysis. This strategy is
exemplified with bitopertin. A systematic knowledge of
ethnic variations in physiology, enzymes and transporters
is required for successful application of this strategy.
2 Methods
2.1 General
PBPK simulations were performed using the Simcyp
Population-Based Simulator version 14 (Simcyp Ltd,
Sheffield, UK). PopPK analysis was conducted using
NONMEM version 7.2 (Icon Development Solutions,
Hanover, MD, USA).
2.2 Clinical Data
The study included 101 healthy adult subjects (61 Cau-
casians, 16 Chinese and 24 Japanese) from four clinical
pharmacokinetic studies. Two studies were conducted in
Caucasian subjects, one study in Chinese subjects and one
study in Japanese subjects. In these studies, a single dose of
bitopertin, ranging from 3 to 240 mg, was administered
orally to fasting individuals. The study details are sum-
marized in Table 1. All studies were approved by inde-
pendent ethics committees, and all study participants
provided written informed consent before enrolment.
2.3 PBPK Model
The original bitopertin PBPK model was built pre-clini-
cally using GastroPlusTM version 8.0 (Simulations Plus,
Inc., Lancaster, CA, USA) and was used for the first pre-
diction of human pharmacokinetics as described by Parrott
et al. [7]. For use in ethnic sensitivity simulations, we
transferred the model to Simcyp, where ethnic popula-
tions are available for Caucasian, Chinese and Japanese.
The input parameters for the bitopertin model are sum-
marized in Electronic Supplementary Material Table 1.
Table 1 Details of the in vivo studies in healthy Caucasians, Chinese and Japanese
Ethnicity Study no. Dose [mg] n Study design
Caucasian 1 20 12 Open-label, 2-period, drug–drug interaction study
2 3, 6, 12, 24, 50, 80, 120, 180, 240 49 Double-blind, single-dose study
Chinese 3 10, 20 16 Open-label, single-dose, cross-over study
Japanese 4 3, 10, 30, 80 24 Single-blind, single-dose study
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Since the focus of this study was to assess ethnic differ-
ences in oral clearance (CL/F), the GastroPlusTM absorp-
tion model was replaced by a simple first-order absorption
model using the absorbed fraction of the dose (Fa), based
on the dose-dependent values reported [7]. The absorption
rate constant (Ka) was the geometric mean (GM) value
estimated on the basis of the concentration data in Cau-
casians, using Phoenix software (WinNonlin models ver-
sion 6.4, Pharsight Corp., Cary, NC, USA). The variability
in Ka was large (coefficient of variation [CV] 73.3 %). The
same Ka was used at different dose levels for PBPK sim-
ulations in the three ethnicities. The demographic data-
bases of Caucasians, Chinese and Japanese were as
provided in Simcyp. Fa at the same dose level, the
intrinsic catalytic activity of CYP3A4 per unit amount of
enzyme variant and tissue composition was assumed to be
the same in Caucasians, Chinese and Japanese. The mean
abundances of CYP3A4 in the liver in Caucasians, Chinese
and Japanese were 137, 120 and 122 pmol/mg, respectively
[9, 10]. The liver weight was estimated on the basis of the
body surface area (BSA) [liver weight = 0.722 9
BSA1.176] with an additional scalar of 0.85 in Chinese,
based on literature indicating that Chinese have signifi-
cantly smaller livers than Caucasians and Japanese [9].
Within Simcyp, we set the age range and proportion of
female subjects for the selected ethnic populations and then
allowed Simcyp to use its built-in algorithms and equa-
tions to generate virtual populations similar to the actual
study populations. The details of how Simcyp generates a
population have been described by Howgate et al. [11].
The simulations followed the reported study designs and
conditions as closely as possible, including the numbers of
subjects, pharmacokinetic sampling duration, route of
administration, dose and fasted/fed status. Ten trial simu-
lations were performed for each study.
After the bitopertin PBPK model was evaluated, CL/
F of 20 mg of bitopertin in the age range of 20–70 years,
with 50 % female subjects, was simulated in Caucasians
(n = 1000), Chinese (n = 1000) and Japanese (n = 1000),
and was used to assess ethnic differences.
2.4 PopPK Model
Population pharmacokinetic analysis was performed using
nonlinear mixed-effects modelling with first-order condi-
tional estimation with interaction (FOCEI). Models were
statistically compared using a likelihood ratio test (LRT) on
the difference in the objective function value (OFV). Sta-
tistical significance was set at p\ 0.01 (DOFV[6.63). The
slightly less than dose-proportional increase in the area
under the plasma concentration–time curve (AUC) [non-
compartmental analysis] over the dose range of 3–240 mg in
Caucasians was assumed to be caused by a nonlinear Fa
rather than nonlinear elimination [7]. Therefore, the effect of
the dose onFa was described using a nonlinear model, andFa
relative to that of the lowest dose at different dose levels was
estimated. To describe the nonlinearity in the maximum
plasma drug concentration (Cmax) and AUC at different
magnitudes, a saturable Michaelis–Menten absorption
model was used. Exponential errors following a log-normal
distribution were used to describe the between-subject
variability (BSV) in the pharmacokinetic parameters. A
combined proportional and additive error model was used to
describe the residual unexplained variability (RUV). The
effects of demographic factors (age, weight, BSA, height,
body mass index [BMI], sex and ethnicity) on the model
parameters were investigated to explain the variability. A
stepwise forward inclusion procedure (p\ 0.01; decrease in
OFV[6.63) was performed to build the full model, and a
stepwise backward elimination procedure (p\ 0.001;
increase in OFV[10.83) was applied to determine the final
model. The final model was evaluated using a visual pre-
dictive check (VPC): a total of 1000 data sets were simulated
using the parameter estimates in the final model.
2.5 Statistical Analysis
Population pharmacokinetic parameters are generally
considered to be log normally distributed. Hence, the val-
ues of the geometric means and 95 % confidence intervals
(CIs) were used to compare CL/F.
CL/F was calculated from a non-compartmental analysis
for the observed and PBPK-simulated concentration–time
data, using Phoenix software. The figures were drawn using




The demographics of the Caucasian, Chinese and Japanese
subjects in the in vivo studies can be seen in Table 2.
3.2 PBPK Model Evaluation
The geometric mean CL/F predicted by the PBPK model in
the Caucasian, Chinese and Japanese populations after
administration of different dose levels of bitopertin can be
seen in Table 3. All ratios of predicted to observed geo-
metric mean CL/F values were within 2-fold in the three
populations. Most (13/16) of the ratios were within
0.8–1.25 in Caucasians, except at the 6, 20 and 240 mg
dose levels. All of the ratios were within 0.8–1.25 in the
Chinese and Japanese populations.
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These simulations demonstrated that bitopertin PBPK
models were able to predict CL/F of bitopertin well.
3.3 Prediction of Ethnic Sensitivity in Clearance,
Using PBPK Modelling
The demographics of the 1000 simulated Caucasian, Chi-
nese and Japanese subjects can be seen in Electronic
Supplementary Material Table 2. The predicted geometric
mean CL/F values in Caucasian, Chinese and Japanese
populations after administration of 20 mg of bitopertin in
the age range of 20–70 years, with a proportion of females
of 0.5, were 4.99 (95 % CI 4.81–5.17) L/h, 3.79 (95 % CI
3.66–3.91) L/h and 3.94 (95 % CI 3.80–4.10) L/h,
respectively.
The predicted geometric mean CL/F values in Cau-
casians were 1.32-fold and 1.27-fold higher than the values
in Chinese and Japanese, respectively. The body weight–
normalized predicted geometric mean CL/F values in the
Caucasian, Chinese and Japanese populations were 0.0670,
0.0624 and 0.0675 L/h/kg, respectively, which were very
similar to each other.
3.4 Assessment of Ethnic Effects in Clearance,
Using PopPK Analysis
A total of 1675 plasma concentration measurements (900
measurements from Caucasians, 478 from Chinese and 297
from Japanese) were used for population pharmacokinetic
model development. The pharmacokinetics of bitopertin
were best described by a two-compartment model incor-
porating a saturable Michaelis–Menten kinetic absorption
process and dose-adjusted Fa.
The data did not support the assignment of BSV to the
maximum absorption rate constant (Ka,Max), the dose with
half of the maximum absorption rate constant (Ka,50), the
Table 2 Demographics of healthy Caucasian, Chinese and Japanese subjects in the in vivo studies
Ethnicity Study no. n Male/female Age [years]a Weight [kg]a BMI [kg/m2]a,b BSA [m2]a,c
Caucasian 1 12 12/0 46 (20–62) 79.7 (71.0–95.0) 26.1 (23.0–29.4) 1.95 (1.78–2.23)
2 49 49/0 22 (18–35) 78.1 (60.0–99.0) 24.0 (19.9–28.9) 1.98 (1.72–2.32)
Chinese 3 16 8/8 30 (23–39) 62.5 (56.3–73.1) 23.7 (20.7–26.5) 1.67 (1.52–1.90)
Japanese 4 24 24/0 24 (20–32) 64.5 (51.0–74.2) 21.4 (18.7–24.6) 1.78 (1.55–1.92)
BMI body mass index, BSA body surface area
a Data are shown as mean (range)
b BMI was calculated as weight [kg]/height [m]2
c BSA was calculated using the Du Bois and Du Bois formula: BSA = weight [kg]0.425 9 height [cm]0.725 9 0.007184
Table 3 Details of the
observed and physiologically
based pharmacokinetic model–
predicted geometric mean oral
clearance (CL/F) values in
healthy Caucasian, Chinese and
Japanese subjects in the in vivo
studies
Ethnicity n Dose [mg] Observed CL/F [L/h]a Predicted CL/F [L/h]a Ratiob
Caucasian 12 20 4.09 (3.19–5.25) 5.63 (5.09–6.23) 1.38
4 3 5.34 (4.09–6.96) 6.35 (5.22–7.73) 1.19
6 6 3.99 (3.48–4.58) 5.97 (5.15–6.91) 1.50
6 12 6.25 (3.94–9.91) 6.35 (5.49–7.34) 1.02
4 24 4.82 (3.29–7.06) 5.68 (4.67–6.91) 1.18
6 50 6.26 (4.21–9.31) 6.50 (5.61–7.53) 1.04
6 80 6.30 (5.42–7.32) 6.79 (5.88–7.84) 1.08
6 120 6.45 (4.91–8.49) 7.29 (6.22–8.55) 1.13
5 180 9.30 (6.95–12.5) 9.44 (7.82–11.4) 1.02
6 240 6.67 (5.29–8.43) 10.4 (8.75–12.3) 1.56
Chinese 16 10 4.40 (3.70–5.23) 3.79 (3.52–4.07) 0.86
16 20 4.44 (3.81–5.18) 3.79 (3.53–4.07) 0.85
Japanese 6 3 4.16 (3.77–4.59) 4.91 (4.20–5.73) 1.18
6 10 4.57 (3.61–5.78) 5.03 (4.31–5.88) 1.10
6 30 4.13 (3.61–4.74) 4.92 (4.21–5.74) 1.19
6 80 4.91 (4.04–5.96) 5.17 (4.39–6.07) 1.05
a Data are shown as geometric mean (95 % confidence interval)
b Ratio of predicted to observed CL/F
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absorption lag time (tlag) and the dose with half of the
absorbed fraction of the 3 mg dose (Fa,50). The additive
component was removed from the RUV because it was
negligible.
BMI was identified as a covariate on the peripheral
distribution volume (V3/F). Body weight, BSA, age, sex
and BMI had no significant effect on CL/F. Lastly, the
effect of ethnicity was evaluated as a covariate on CL/
F with a decrease of 6.03 in OFV. The estimated CL/
F ratios of Chinese and Japanese to Caucasians were 0.833
and 0.858, respectively. Because the effect was not sig-
nificant, it was not included in the final model. The esti-
mated CL/Fadjusted (CL/Fadjusted = Fa,relative 9 dose/AUC,
where Fa,relative is the Fa of a different dose relative to
3 mg) and body weight–normalized CL/Fadjusted in Cau-
casian, Chinese and Japanese populations can be seen in
Fig. 1. Parameter estimates of the final model are sum-
marized in Table 4.
The accuracy and robustness of the final model were
evaluated using a VPC, and the final model adequately
described the pharmacokinetic profile of bitopertin (Fig. 2).
3.5 Comparison of Predicted Clearance Values
Between PBPK and PopPK Modelling
The predicted clearance values according to PBPK mod-
elling and popPK analysis were compared using the
demographics of the real studies. No same dose level was
investigated in the three ethnic populations. The pharma-
cokinetic results after 10 and 20 mg, the dose levels that
were used in phase 3 trials, were used for the comparison.
The PBPK modelling–predicted bitopertin geometric mean
CL/F values after administration of 20, 10 and 10 mg in
Caucasian, Chinese and Japanese populations were 5.63,
3.79 and 5.03 L/h, respectively (Table 3). The PopPK
analysis estimated CL/Fadjusted values of 5.28 and 5.22 L/h
Fig. 1 Box plots of individual
oral clearance (CL/F)
values (a) and body weight–
normalized CL/





bitopertin in the final model
Parameter Estimate (RSE %) BSV [CV % (RSE %)]
CL/F [L/h] 5.17 (3.6) 32.1 (18.8)
V2/F [L] 32.1 (12.4) 82.2 (25.4)
Q/F [L/h] 19.6 (4.1) 17.2 (38.0)
V3/F [L] 256 (3.3) 20.8 (20.1)
Exponent of BMI on V3/F 2.01 (10.2)
Ka,Max [1/h] 30.1 (13.5) –
Ka,50 [mg] 105 (16.9) –
tlag [h] 0.249 (0.1) –
Fa,50 [mg] 774 (28.1) –
RUV [ %] 26.0 (8.0)
BMI body mass index, BSV between-subject variability, CL/F oral clearance, CV coefficient of variation,
Fa,50 dose with half of the absorbed fraction of the 3 mg dose, Ka,50 dose with half of the maximum
absorption rate constant, Ka,Max maximum absorption rate constant, Q/F inter-compartmental clearance,
RSE relative standard error, RUV residual unexplained variability, tlag absorption lag time, V2/F central
distribution volume, V3/F peripheral distribution volume
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without considering the effect of ethnicity for the 20 mg
and 10 mg doses, respectively. The ratios of the geometric
mean clearance values predicted by PBPK modelling to the
CL/Fadjusted estimated by popPK analysis in Caucasian,
Chinese and Japanese populations were 1.07, 0.73 and
0.96, respectively. When ethnicity was incorporated as a
covariate, the popPK analysis–estimated CL/Fadjusted val-
ues in Caucasian, Chinese and Japanese populations were
5.55, 4.68 and 4.84 L/h, respectively. The ratios of the
geometric mean clearance values predicted by PBPK
modelling to the CL/Fadjusted values estimated by popPK in
Caucasian, Chinese and Japanese populations were 1.01,
0.81 and 1.04, respectively. The relatively larger difference
in the ratio between the two methods in Chinese may have
come from the additional correction of 0.85 that was used
to estimate the liver weight in Chinese on the basis of BSA
[9]. Further confirmation of liver weight in Chinese is
required.
Fig. 2 Visual predictive checks of the final population pharmacoki-
netic model: results from 1000 simulated data sets. The blue circles
represent observations. The solid red lines represent the 50th
percentiles of the simulated profiles, and the dashed red lines
represent the 5th and 95th percentiles. Conc concentration
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3.6 Comparison of Simulated Pharmacokinetic
Profile Between PBPK and PopPK Modelling
The simulated plasma concentration–time curves after oral
administration of 20, 10 and 10 mg in Caucasian, Chinese
and Japanese populations according to PBPK modelling
and popPK analysis (using the model without ethnicity as a
covariate) can be seen in Fig. 3. The plasma concentration–
time curves simulated by PBPK modelling and popPK
analysis (using the model without ethnicity as a covariate)
were similar to each other and were in good agreement
with the observed data. The comparisons of PBPK mod-
elling and popPK analysis for bitopertin pharmacokinetic
prediction can be seen in Table 5.
4 Discussion
Assessing the sensitivity of a medicine’s PK/PD to ethnic
factors is the key to extrapolating safety and efficacy from
one region to another. Currently, in China and Japan,
because of lack of understanding of the underlying mech-
anisms of ethnic differences, almost all drugs need to be
assessed for ethnic sensitivity through conduct of bridging
PK/PD studies, consuming significant amounts of resource
and time. The current method for ethnic sensitivity
assessment is empirical, molecule based and fragmental. It
cannot be used to predict the ethnic sensitivity of NMEs.
We propose a different strategy for NMEs (see Fig. 4: the
right two triangles—NME focused), whereby bottom-up
and top-down modelling approaches are applied in a
sequential and complementary fashion. First, at the pre-
clinical stage, mechanistic understanding of the molecule
and its clearance pathways will serve as the input for PBPK
modelling to predict ethnic sensitivity. The prediction will
guide the early planning of ethnic bridging studies and/or
assist dosing decision making and trial design, as well as
directing enrolment of different ethnicities in phase 3
studies. Then, when pharmacokinetic data in multiple
ethnicities are available, popPK analysis can be used to
confirm the PBPK modelling results and provide confir-
matory evidence for drug label. The bitopertin PBPK
Fig. 3 Simulated (lines) and
observed (black circles) mean
plasma concentration (Conc)–
time curves (a, c, e) and
absorption phase (b, d, f) of
bitopertin in healthy
Caucasians, Chinese and
Japanese. The light grey lines
represent the means of the
simulations of individual trials
(10 trials) according to
physiologically based
pharmacokinetic (PBPK)
modelling. The solid black lines
represent the means for the total
virtual population according to
PBPK modelling, and the dotted
black lines represent the 5th and
95th percentiles. The dashed red
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model was developed to simulate pharmacokinetics in
Caucasian and Asian populations and to predict ethnic
differences when there were only pharmacokinetic data in
Caucasians. Subsequently, a popPK model was developed
to assess the effects of ethnicity on pharmacokinetic
parameters when human data from multiple ethnic groups
were available to confirm the PBPK modelling results. The
popPK model built on the basis of phase 1 data was con-
sistent with the graphical analysis of the phase 3 data
(unpublished data).
PBPK modelling predicted that the bitopertin geometric
mean CL/F values after administration of 20 mg in the age
range of 20–70 years would be 1.32-fold and 1.27-fold
higher than the values in Chinese and Japanese, respec-
tively. When ethnicity was incorporated as a covariate, the
popPK analysis found that the ratios of typical clearance in
Caucasians to the values in Chinese and Japanese were
1.20 and 1.17, respectively. The body weight–normalized
CL/F was similar (Fig. 1). Thus, the popPK analysis results
were similar to the PBPK modelling results.
For NMEs involving well-defined pharmacokinetic
processes with well-established PBPK models, especially
for those low-ethnic-sensitivity pathways that are defined,
dedicated pharmacokinetic bridging studies may not be
needed. For high-ethnic-sensitivity compounds, dose
decisions may still need dedicated bridging studies. Sub-
sequently, data from later-stage clinical trials can be used
to build a popPK model to confirm the PBPK modelling
results on ethnic differences, providing a more efficient
way to address potential ethnic pharmacokinetic
differences.
The well-established PBPK model for the CYP3A4
pathway ensured successful ethnic sensitivity prediction for
bitopertin. For successful application of the proposed
strategy on a broad scale, the ethnic-specific system data
are yet to be collected and PBPK models of the major
pharmacokinetic processes need to be validated. It is gen-
erally believed that PBPK models for CYP enzymes are
reasonably well established [9, 10, 12], but the data on the
gastrointestinal tract (e.g. enzymes, transporters, fluid
dynamics), phase II metabolic enzymes and transporter-
mediated pharmacokinetic pathways—and those data in
special populations (e.g. paediatric subjects, and subjects
with renal or hepatic impairment)—are still limited. We
proposed that an academic–industry–regulatory consortium
Table 5 Comparisons of physiologically based pharmacokinetic (PBPK) modelling and population pharmacokinetic (popPK) analysis for
bitopertin pharmacokinetic (PK) prediction
PK process PBPK modelling PopPK analysis
Absorption Ka was 1.95 h
-1
Fa values were 0.999 (10 mg) and 0.995 (20 mg)
Relative bioavailability values of 10 and 20 mg to 3 mg were both 1.00a
tlag was 0.456 h
Ka values were 0.261 h
-1 (10 mg) and 0.241 h-1
(20 mg)
Relative bioavailability values of 10 mg and
20 mg to 3 mg were 0.99 and 0.98, respectively
tlag was 0.249 h
Distribution Vss was estimated at 2.85 L/kg, using Kp measured in the rat [7] Typical V2/F and V3/F were 32.1 and 256 L,
respectively
Metabolism Intrinsic clearance (0.410 lL/min/pmol)b of the CYP3A4 isoform was used
to scale up to CL/F
Geometric mean CL/F values after administration of 20, 10 and 10 mg in
Caucasian, Chinese and Japanese populations, respectively, were 5.63, 3.79
and 5.03 L/h, respectively
Typical CL/F was 5.17 L/h
CL/F oral clearance, CYP3A4 cytochrome P450 3A4, Fa absorbed fraction of the dose, Ka absorption rate constant, Kp tissue-to-plasma partition
coefficient, tlag absorption lag time, V2/F central distribution volume, V3/F peripheral distribution volume, Vss steady-state distribution volume
a The relative bioavailability was calculated using the predicted data from the PBPK model [7]
b The intrinsic clearance value was obtained using a retrograde approach
Fig. 4 Scheme to assess ethnic sensitivity, using physiologically
based pharmacokinetic modelling (a ‘bottom-up’ approach) and
population pharmacokinetic analysis (a ‘top-down’ approach).
NME new molecular entity, PK pharmacokinetic
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should be established to further investigate ethnic differ-
ences in absorption, distribution, metabolism and excretion
(ADME) pathways and to enable improved PBPK mod-
elling of the effects of ethnicity for a wide range of NMEs.
The consortium would start by building a database of the
effects of ethnicity on probe drugs for known clearance
mechanisms (see Fig. 4: the left two triangles—pharma-
cokinetic-pathway focused). PopPK analysis can then be
used as a screening tool to identify pharmacokinetic path-
ways that have significant ethnic differences. To probe the
physiological factors causing the difference, PBPK models
can be developed, refined and validated through a number
of probe drugs with the same pharmacokinetic pathway,
using full data sets of multiple ethnic groups. Once a set of
such PBPK models is established for major pharmacoki-
netic processes, one can predict ethnic sensitivity for a
given NME even with multiple pharmacokinetic pathways.
Bitopertin is an ideal probe drug for CYP3A4 because it
is predominantly eliminated by hepatic CYP3A4 metabo-
lism with a limited gut first-pass effect [7]. In this study,
the ratios of typical clearance (not adjusted for body
weight) in Caucasians to the values in Chinese and Japa-
nese estimated by popPK analysis were 1.20 and 1.17,
respectively. This was similar to the reported results for
alprazolam, another CYP3A substrate [9]. The observed
geometric mean alprazolam clearance value estimated
using non-compartmental analysis in Caucasians was 1.27-
fold higher than the value in Chinese. The body weight–
normalized median alprazolam clearance values estimated
using non-compartmental analysis were similar in Cau-
casians and Japanese [10]. This may indicate that the
CYP3A4 activity in the liver in Caucasians was compara-
ble to the values in Chinese and Japanese, which may be
explained by the similar abundance of CYP3A4 in the three
ethnic populations and can help to predict the ethnic sen-
sitivity of CYP3A4 substrates (e.g. NMEs) in pharma-
cokinetics, using PBPK modelling. The difference in
clearance due to hepatic blood flow and liver weight can be
reflected in the body size. Therefore, the body weight–
normalized clearance values for bitopertin were similar in
the three ethnicities that were studied.
A more advanced absorption model (the advanced dis-
solution, absorption and metabolism [ADAM] model) has
already been implemented in Simcyp. In theory, it can be
used to predict ethnic differences in absorption. However,
the available physiological databases on ethnic differences
in the gastrointestinal tract are very limited; thus, no rele-
vant physiological differences exist in the Simcyp models
for different ethnicities. Therefore, we focus on the ethnic
difference in clearance and choose the simple absorption
model for bitopertin.
Although bitopertin PBPK models can capture most of
the observed clearance values in Caucasians, Chinese and
Japanese at different dose levels, it should be pointed out
that data on the physiology, enzymes and transporters in
Chinese and Japanese are still limited. More system data
are needed and should be evaluated before the data are used
for complex pharmacokinetic prediction. Ethnic differ-
ences in pharmacokinetics are just one component of ethnic
sensitivity; comparability in disease biology, epidemiology
and medical practice should be examined as well to ulti-
mately elucidate ethnic differences in drug safety and
efficacy.
5 Conclusion
PBPK modelling accurately predicted *1.2-fold differ-
ences in the clearance of bitopertin between Caucasians
and Asians without body weight adjustment, which was
confirmed by the popPK analysis. As a general framework,
PBPK modelling should be considered to predict ethnic
sensitivity of pharmacokinetics prior to any human data
and/or with data in only one ethnicity. Subsequently,
popPK analysis can be used to confirm the effect of eth-
nicity and to support dose justification and labelling. PBPK
modelling prediction and popPK analysis confirmation can
complement each other for assessment of ethnic differ-
ences in clearance at different drug development stages.
However, successful application of the strategy may be
facilitated by an academic–industry–regulatory consortium
to collect sufficient ethnic-specific system data and to
validate PBPK models of the major pharmacokinetic
processes.
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